Current status of maintenance therapy for advanced ovarian cancer

Por Hope, Joanie Mayer, Blank, Stephanie V
Publicado em 2010

Coronavirus concerns: What do women with gynecologic cancer need to know during the COVID-19 crisis?

Por Frey, Melissa K., Blank, Stephanie V.
Publicado no Gynecol Oncol (2020)

Occult tubal carcinoma found at risk reducing salpingectomy in a BRCA1 carrier()

Por Kim, Sarah H., Frey, Melissa K., Blank, Stephanie V.
Publicado em 2014

Breast cancer in the setting of fertility-sparing treatment for endometrial cancer

Por Moss, Haley A., Frey, Melissa K., Blank, Stephanie V.
Publicado no Gynecol Oncol Rep (2014)

Primary breast cancer of the vulva with concurrent breast and endometrial cancers: A case report and literature review

Por Li, Sue, Schwartz, Melissa, Everest, Sedef, Blank, Stephanie V.
Publicado no Gynecol Oncol Rep (2018)

“Best practices in risk reducing bilateral salpingo-oophorectomy: the influence of surgical specialty”

Por Malacarne, Dominique R., Boyd, Leslie R., Long, Yang, Blank, Stephanie V.
Publicado no World J Surg Oncol (2017)

Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer

Por Korets, Sharmilee Bansal, Musa, Fernanda, Curtin, John, Blank, Stephanie V., Schneider, Robert J.
Publicado no Gynecol Oncol (2013)

The influence of BRCA variants of unknown significance on cancer risk management decision-making

Por Chern, Jing-Yi, Lee, Sarah S., Frey, Melissa K., Lee, Jessica, Blank, Stephanie V.
Publicado no J Gynecol Oncol (2019)

Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer

Por Aghajanian, Carol, Goff, Barbara, Nycum, Lawrence R., Wang, Yan V., Husain, Amreen, Blank, Stephanie V.
Publicado no Gynecol Oncol (2015)

Dual mTORC1/2 inhibition as a novel strategy for the re-sensitization and treatment of platinum-resistant ovarian cancer

Por Musa, Fernanda, Alard, Amandine, David-West, Gizelka, Curtin, John P., Blank, Stephanie V., Schneider, Robert J.
Publicado no Mol Cancer Ther (2016)

Estrogen and Progesterone Regulate p27kip1 Levels via the Ubiquitin-Proteasome System: Pathogenic and Therapeutic Implications for Endometrial Cancer

Por Huang, Kuang-Tzu, Pavlides, Savvas C., Lecanda, Jon, Blank, Stephanie V., Mittal, Khushbakhat R., Gold, Leslie I.
Publicado em 2012

Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment

Por Blank, Stephanie V., Christos, Paul, Curtin, John P., Goldman, Noah, Runowicz, Carolyn D., Sparano, Joseph A., Liebes, Leonard, Chen, Helen X., Muggia, Franco M.
Publicado em 2010

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian,...

Por Aghajanian, Carol, Blank, Stephanie V., Goff, Barbara A., Judson, Patricia L., Teneriello, Michael G., Husain, Amreen, Sovak, Mika A., Yi, Jing, Nycum, Lawrence R.
Publicado em 2012

Inhibitors of SCF-Skp2/Cks1 E3 Ligase Block Estrogen-Induced Growth Stimulation and Degradation of Nuclear p27(kip1): Therapeutic Potential for Endometrial Cancer

Por Pavlides, Savvas C., Huang, Kuang-Tzu, Reid, Dylan A., Wu, Lily, Blank, Stephanie V., Mittal, Khushbakhat, Guo, Lankai, Rothenberg, Eli, Rueda, Bo, Cardozo, Timothy, Gold, Leslie I.
Publicado em 2013

A Phase II Study of Oxaliplatin Combined with Continuous Infusion Topotecan for Patients with Previously Treated Ovarian Cancer

Por Stein, Stacey M., Tiersten, Amy, Hochster, Howard S., Blank, Stephanie V., Pothuri, Bhavana, Curtin, John, Shapira, Ilan, Levinson, Benjamin, Ivy, Percy, Joseph, Benson, Guddati, Achuta K., Muggia, Franco
Publicado em 2013

Impact of the coronavirus disease 2019 pandemic on the quality of life for women with ovarian cancer

Por Frey, Melissa K., Ellis, Annie E., Zeligs, Kristen, Chapman-Davis, Eloise, Thomas, Charlene, Christos, Paul J., Kolev, Valentin, Prasad-Hayes, Monica, Cohen, Samantha, Holcomb, Kevin, Blank, Stephanie V.
Publicado no Am J Obstet Gynecol (2020)

Phase I and Pharmacokinetic Study of Veliparib, a PARP Inhibitor, and Pegylated Liposomal Doxorubicin (PLD) in Recurrent Gynecologic Cancer and Triple Negative Breast Cancer with L...

Por Pothuri, Bhavana, Brodsky, Allison L, Sparano, Joseph A, Blank, Stephanie V, Kim, Mimi, Hershman, Dawn L, Tiersten, Amy, Kiesel, Brian F, Beumer, Jan H, Liebes, Leonard, Muggia, Franco
Publicado no Cancer Chemother Pharmacol (2020)

Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors

Por Roudko, Vladimir, Bozkus, Cansu Cimen, Orfanelli, Theofano, McClain, Christopher B., Carr, Caitlin, O’Donnell, Timothy, Chakraborty, Lauren, Samstein, Robert, Huang, Kuan-lin, Blank, Stephanie V., Greenbaum, Benjamin, Bhardwaj, Nina
Publicado no Cell (2020)

Adapting and avoiding coping strategies for women with ovarian cancer during the COVID-19 pandemic

Por Frey, Melissa K., Chapman-Davis, Eloise, Glynn, Shannon M., Lin, Jenny, Ellis, Annie E., Tomita, Shannon, Fowlkes, Rana Khan, Thomas, Charlene, Christos, Paul J., Cantillo, Evelyn, Zeligs, Kristen, Holcomb, Kevin, Blank, Stephanie V.
Publicado no Gynecol Oncol (2021)

Paclitaxel Plus Oxaliplatin for Recurrent or Metastatic Cervical Cancer: A New York Cancer Consortium Study

Por Kuo, Dennis Yi-Shin, Blank, Stephanie V., Christo, Paul J., Kim, Mimi, Caputo, Thomas A., Pothuri, Bhavana, Hershman, Dawn, Goldman, Noah, Ivy, Percy S., Runowicz, Carolyn D., Muggia, Franco, Goldberg, Gary L., Einstein, Mark H.
Publicado em 2009